Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | FLT1 | P17948 | 2/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622372 | 0.89 | FGFR1 (0.69) | FGFR1FLT1HRH4DRD3CHEK2 | |
| SCHEMBL13869880 | 0.89 | FGFR1 (0.61) | FGFR1FLT1HRH4DRD3CHEK2 | |
| SCHEMBL13869876 | 0.85 | FGFR1 (0.55) | FGFR1FLT1HRH4DRD3CHEK2 | |
| SCHEMBL1621132 | 0.85 | LCK (0.50) | FGFR1FLT1DRD3DRD2AURKA | |
| SCHEMBL1623203 | 0.83 | KDR (0.53) | FGFR1FLT1DRD3AURKAKDR | |
| SCHEMBL1621731 | 0.80 | LCK (0.48) | FGFR1FLT1DRD3DRD2AURKA | |
| SCHEMBL1622655 | 0.79 | KDR (0.47) | FGFR1FLT1AURKAKDRHRH3 | |
| SCHEMBL1623222 | 0.76 | ITK (0.45) | FGFR1FLT1DRD3DRD2HRH3 | |
| SCHEMBL12748914 | 0.75 | HRH3 (0.40) | DRD3AURKAKDRACHEHRH3 | |
| SCHEMBL13869882 | 0.74 | FGFR1 (0.43) | FGFR1FLT1HRH4CHEK2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | FGFR1 846/4885FLT1 1207/4885HRH4 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.